Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with chemoradiotherapy for muscle-invasive bladder cancer
ISRCTN80733590Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Nov 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of cetuximab, fluorouracil, mitomycin c and cisplatin in bladder cancer (3 cohorts), sponsored by University of Birmingham. Primary endpoint: Feasibility and toxicity. Started Nov 2011; status: completed.
02
Drugs
cetuximabfluorouracilmitomycin ccisplatin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ISRCTN80733590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80733590.